CAMBRIDGE, Mass., April 2, 2024 /PRNewswire/ -- Marengo Therapeutics, Inc, a clinical-stage biotech company pioneering a new way to activate T cells that target the Vβ chain of the T cell receptor (TCR) and select the right T cell subsets against cancer, today announced that Ipsen (Euronext: IPN; ADR: IPSEY) has nominated the first clinical drug candidate (DC) of two from its multi-year strategic partnership in oncology..

马萨诸塞州剑桥市，2024年4月2日/PRNewswire/-Marengo Therapeutics，Inc，一家临床阶段生物技术公司，开创了一种新的方法来激活靶向T细胞受体（TCR）Vβ链的T细胞并选择正确的T细胞亚群对抗癌症，今天宣布Ipsen（Euronext:IPN；ADR:IPSEY）已从其多年的肿瘤学战略合作伙伴关系中提名了两个临床候选药物（DC）。。

This clinical candidate reflects a productive collaboration since the strategic partnership was signed in August 2022. Marengo and Ipsen plan to advance the program through IND-enabling studies and into clinical development. This nomination represents the first of two selective T cell activation repertoire (STAR) T cell bi-functional activator programs that Marengo and Ipsen will advance as part of the collaboration..

该临床候选人反映了自2022年8月签署战略伙伴关系以来的富有成效的合作。Marengo和Ipsen计划通过IND使能研究和临床开发来推进该计划。这一提名代表了马伦戈和益普生将作为合作的一部分推进的两个选择性T细胞激活库（STAR）T细胞双功能激活程序中的第一个。。

'The DC nomination is a testament to our close partnership with Ipsen and to the expertise and dedication of Marengo's R&D team,' said Zhen Su, M.D., MBA, Chief Executive Officer of Marengo. 'It underscores the potential of our STAR TCR Vb T cell activator platform to deliver a range of first-in-class precision T cell bispecific antibodies for the treatment of refractory solid tumors.

Marengo首席执行官、MBA医学博士甄苏（Zhen Su）说，DC提名证明了我们与Ipsen的密切合作关系，也证明了Marengo研发团队的专业知识和敬业精神它强调了我们的STAR TCR Vb T细胞激活剂平台的潜力，可以提供一系列一流的精密T细胞双特异性抗体，用于治疗难治性实体瘤。

We look forward to the next phase of the collaboration as we work to advance treatment options for patients living with cancer.'.

随着我们努力推进癌症患者的治疗选择，我们期待着下一阶段的合作。”。

Under the terms of the agreement, Marengo will receive a milestone payment for this pre-defined pre-clinical milestone. Marengo is leading the research and preclinical development efforts while Ipsen will assume responsibilities for regulatory submissions, clinical development and commercialization..

根据协议条款，Marengo将收到这个预定义的临床前里程碑的里程碑付款。Marengo正在领导研究和临床前开发工作，而Ipsen将负责监管提交，临床开发和商业化。。

About Marengo Therapeutics

关于Marengo Therapeutics

Marengo Therapeutics, Inc, a clinical-stage biotech company, develops novel TCR-targeting antibodies that selectively modulate common and disease-specific T cell subsets of the germline TCR repertoire to provide lifelong protection against cancer and other diseases. With a passionate team of dedicated scientists experienced in immunology and oncology, Marengo's proprietary Selective T Cell Activation Repertoire (STAR) platform leverages an extensive biological understanding of T cell function and receptor signaling to create a world in which everyone's immune system can defeat cancer.

临床阶段生物技术公司Marengo Therapeutics，Inc开发了新型TCR靶向抗体，可选择性调节种系TCR库的常见和疾病特异性T细胞亚群，从而为癌症和其他疾病提供终身保护。凭借一支在免疫学和肿瘤学领域经验丰富的热诚科学家团队，马伦戈专有的选择性T细胞激活库（STAR）平台利用对T细胞功能和受体信号传导的广泛生物学理解，创造了一个每个人的免疫系统都可以战胜癌症的世界。

About STAR™ Platform

关于STAR™平台

Marengo's STAR™ Platform is a multi-specific antibody-fusion platform derived from Marengo's proprietary library of antibodies targeting germline-encoded variable (V)β regions of the TCR fused to different T cell co-stimulatory moieties. Combining a novel non-clonal mode of TCR activation with a T cell co-stimulator in the same molecule, promotes a distinct mechanism of action that promotes durable anti-tumor Vβ T cell responses..

马伦戈的STAR™平台是一种多特异性抗体融合平台，源自马伦戈的专有抗体库，该抗体靶向与不同T细胞共刺激部分融合的TCR的种系编码可变（V）β区域。将TCR激活的新型非克隆模式与同一分子中的T细胞共刺激物相结合，可促进独特的作用机制，从而促进持久的抗肿瘤VβT细胞反应。